Project

Chemopreventive or breast cancer promoting? A comparative transcriptomic, epigenetic and metabonomic study of isoflavones, tamoxifen and raloxifene in healthy breast tissue.

Code
3E025110
Duration
01 October 2010 → 19 January 2014
Funding
Regional and community funding: Special Research Fund, Research Foundation - Flanders (FWO)
Research disciplines
  • Medical and health sciences
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
    • Nursing
    • Biomarker discovery and evaluation
    • Drug discovery and development
    • Medicinal products
    • Pharmaceutics
    • Pharmacognosy and phytochemistry
    • Pharmacology
    • Pharmacotherapy
    • Toxicology and toxinology
    • Other pharmaceutical sciences
    • Endocrinology and metabolic diseases
    • Gynaecology and obstetrics
Keywords
breast cancer phytoestrogens estrogenic responses soy isoflavones epigenetics metabonomics transcriptomics SERM
 
Project description

Upon soy consumption, isoflavones reach exposure levels in human breast tissue at which ERβ agonistic, putative protective, effects may occur. Yet, the clinical implications of these findings require further investigation. This project aims to characterize the differential activation of estrogen-responsive genes between dietary isoflavones and chemopreventive therapeutics in women undergoing breast reduction surgery by a controlled dietary intervention trial.